Pharsight

1. Jatenzo patents expiration

Application	Filing Date	Opposition Party	Legal Status

EP15186752A	2023-04-26	Aera A/S	Granted and Under Opposition

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US11179402	CLARUS	Pharmaceutical delivery systems for hydrophobic drugs and compositions comprising same	Apr, 2026 (2 years from now)
US10617696	CLARUS	Oral testosterone ester formulations and methods of treating testosterone deficiency comprising same	Apr, 2030 (6 years from now)
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11331325	CLARUS	Pharmaceutical delivery systems for hydrophobic drugs and compositions comprising same	Jan, 2027 (3 years from now)
US8241664	CLARUS	Pharmaceutical delivery systems for hydrophobic drugs and compositions comprising same	Mar, 2029 (5 years from now)
US8778916	CLARUS	Oral testosterone ester formulations and methods of treating testosterone deficiency comprising same	Apr, 2030 (6 years from now)
US11426416	CLARUS	Oral testosterone ester formulations and methods of treating testosterone deficiency comprising same	Apr, 2030 (6 years from now)
US10543219	CLARUS	Oral testosterone ester formulations and methods of treating testosterone deficiency comprising same	Apr, 2030 (6 years from now)
US11179403	CLARUS	Oral testosterone ester formulations and methods of treating testosterone deficiency comprising same	Apr, 2030 (6 years from now)
US8492369	CLARUS	Oral testosterone ester formulations and methods of treating testosterone deficiency comprising same	Dec, 2030 (7 years from now)